ASCO GI 2021 | ctDNA as a novel biomarker for MRD in CRC

Arvind Dasari, MD, MS, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of his presentation at the virtual ASCO Gastrointestinal Cancers Symposium 2021, on the potential use of circulating tumor DNA (ctDNA) as a marker for minimal residual disease (MRD). Using colorectal cancer as a model, he discusses how ctDNA could be used as a biomarker in clinical practice to help identify patients at a high risk of recurrence after surgery, helping to avoid unnecessary adjuvant chemotherapy. He also describes how ctDNA could also be used to help revolutionize drug development in the adjuvant setting. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).